68Ga-labeled prostate specific membrane antigen HBED-CC PET/MRI for staging and evaluating the clinicopathological characteristics in newly diagnosed prostate cancer
<sup>68</sup>Ga-PSMA-11 PET/MRI can provide accurate TNM staging for PCa, particularly in local staging. TL-PSMAt accurately evaluate overall tumor burden and aids in diagnosing clinicopathological characteristics in mid-to-late-stage patients, outperforming SUVmax.
Authors
- Shuli Yang (ORCID: https://orcid.org/0000-0002-3155-8061)
- Tao Wu (ORCID: https://orcid.org/0000-0002-8999-9628)
- Xiaoyu Su (ORCID: https://orcid.org/0000-0002-2472-3591)
- Xiao Wang (ORCID: https://orcid.org/0000-0001-8824-6280)
- Feng Qiao (ORCID: https://orcid.org/0000-0002-1704-7257)
- Wenjing Yu (ORCID: https://orcid.org/0000-0003-0972-8172)
- Hui Wang (ORCID: https://orcid.org/0000-0001-6754-5679)
- Gan Zhu
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1186/s40001-025-02567-7
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China